Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Posted: August 14, 2022 at 2:33 am

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022

More:
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Related Posts